[Jiuzhitang: subsidiary Ischemic Stroke Clinical trial enters the second Phase] June 2, Jiuzhitang announced that in January 2021, the company's holding subsidiary Beijing Meike Ischemia tolerance Human Bone Marrow Mesenchymal Stem cells "Clinical trial Notification" officially launched the clinical trial of ischemic stroke. The Ⅰ phase clinical trial (the first phase of the clinical trial) of the project has completed all participants. The results of the trial preliminarily show the safety of ischemia-tolerant human allogeneic bone marrow mesenchymal stem cells in the treatment of patients with chronic ischemic stroke. Based on the current Ⅰ clinical trial data, the drug evaluation center of the State Drug Administration has evaluated the project and agreed to enter the Ⅱ a phase (i.e. the second phase) clinical trial.